Clinical trials: Liraglutide
Diabetes, Healthy
Safety and Tolerability of NN9068 in Healthy Male Volunteers
This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, level of drug exposure and effect of NN9068.
- Trial name
- NCT00983021
- Testing
- insulin degludec/liraglutide, insulin degludec, liraglutide
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)
New effective non-surgical treatments are needed for patients whose obesity and type 2 diabetes (T2DM) do not respond to current medical therapies.
- Conditions
- Type 2 Diabetes, Obesity, Diabesity
- Trial name
- NCT02055014
- Testing
- Liraglutide, Duodenal-jejunal bypass liner - Endobarrier device
- Where
- 4 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- Sandwell & West Birmingham Hospitals NHS Trust
Diabetes, Effects of Liraglutide Administration on Brain Activity
Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI
The main purpose of this study is to help us understand the effects of diabetes medication Liraglutide on weight loss and hunger.
- Conditions
- Diabetes, Effects of Liraglutide Administration on Brain Activity, Weight Loss, Hunger
- Trial name
- NCT01562678
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Beth Israel Deaconess Medical Center
Diabetes Mellitus, Type 2, Diabetes
The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study
The aim of this clinical trial is to assess and compare the effect of insulin detemir in combination with liraglutide and metformin versus insulin detemir in combination with insulin aspart and metformin in subjects with very…
- Trial name
- SIMPLE (NCT01966978)
- Testing
- Metformin, Detemir, Liraglutide
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- University of Texas Southwestern Medical Center
Type 2 Diabetes
Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
Background: Preclinical blood pressure (BP) data from studies of hypoglycemic effects of liraglutide treatment (the LEAD program), revealed a significant antihypertensive potential.
- Trial name
- Liratime (NCT01499108)
- Testing
- liraglutide
- Where
- Denmark
- Volunteers
- 32 people
- Sponsor
- Peter Rossing
Diabetes Mellitus, Type 2
Glucagon-like Peptide (GLP) Utilization and Safety
This study will assess the utilization patterns (adherence, source of the index antidiabetic agent (ADA) and treatment modification) of the marketed glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide and liraglutide)…
- Trial name
- NCT01767389
- Testing
- The GLP-1 receptor agonist users, DPP-4 inhibitor users, Other ADA users
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Maturity-onset Diabetes of the Young
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
The purpose of this study is to evaluate the treatment potential of GLP-1-analogues in patients with Maturity Onset Diabetes of the Young (MODY) compared to common treatment.
- Trial name
- NCT01610934
- Testing
- liraglutide, Glimepiride
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Type 2 Diabetes Mellitus
Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide
The purpose of this study is to determine the effect of exogenous glucagon-like peptide-1 on the immune system i.e on the regulation of immune cells important in diseases such as obesity and diabetes.
- Trial name
- NCT02201550
- Where
- Denmark
- Volunteers
- 9 people
- Sponsor
- Hvidovre University Hospital
Type 2 Diabetes, Overweight
Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes
Obesity is one of the characteristics of type 2 diabetes mellitus. Most of the obese diabetes patients are combined with dyslipidemia or hypertension.
- Conditions
- Type 2 Diabetes, Overweight, Obesity, Masked Hypertension
- Trial name
- NCT02503943
- Testing
- "Liraglutide" and "Mitiglinide", "Metformin" and "Mitiglinide", "Mitiglinide"
- Volunteers
- 90 people
- Sponsor
- Third Affiliated Hospital of Third Military Medical University
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting
This trial is conducted in the United States of America (USA). The purpose of the trial is to investigate the effect and safety of liraglutide 3.0 mg as an adjunct to intensive behaviour therapy for obesity in a non-specialist…
- Trial name
- SCALE™ IBT (NCT02963935)
- Testing
- liraglutide, CMS Intensive Behavior Therapy
- Where
- 10 sites in United States
- Volunteers
- 282 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.
- Trial name
- NCT01511185
- Testing
- liraglutide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Study of LY3025876 in Participants With Diabetes
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01870297
- Testing
- LY3025876, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes
The aim of the study is to investigate the effect of Victoza (a GLP-1 receptor agonist)on insulin-dose, risk of hypoglycemia and gastric emptying rate during hypoglycemia in patients with type 1 diabetes.
- Trial name
- NCT00993720
- Testing
- Liraglutide, continuous insulin therapy
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Hvidovre University Hospital
Osteoarthritis, Obesity
Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
- Trial name
- CIMT-LOSEIT-I (NCT02954627)
- Testing
- Dietary Supplement: Intensive dietary intervention
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Henrik Gudbergsen
Osteoarthritis, Obesity
Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
- Trial name
- IM-LOSEIT-II (NCT02928679)
- Testing
- Liraglutide 3 mg (Saxenda)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Henrik Gudbergsen
Osteoarthritis, Knee
Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis
This is sub-study to a randomised, double blind, placebo-controlled, parallel group, and single-centre trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis…
- Trial name
- NCT02910570
- Testing
- Liraglutide 3 mg (Saxenda)
- Where
- Denmark
- Volunteers
- 150 people
- Sponsor
- Parker Research Institute
Diabetes Mellitus, Type 2
A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM.
- Trial name
- IMPERIUM (NCT02072096)
- Testing
- Glimepiride, Metformin, Pioglitazone
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 192 people
- Sponsor
- Eli Lilly and Company